ClinicalTrials.gg
RecruitingNCT07153809Updated Sep 4, 2025

Fecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis

An interventional study of FMT and Placebo in Acute Pancreatitis and Severe Acute Pancreatitis, sponsored by Changhai Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Pancreatitis by Changhai Hospital — 7 open to participants now, 7 under way, none of them phase 3. Pancreatitis · Changhai Hospital.

Started
2024
with 2 others
No phase
6 of 16
4 open now
Registered
11th of 16
by date

Among the 16 studies in Pancreatitis by Changhai Hospital, this one is one of 3 that started in 2024, is one of 6 with no phase, and was the 11th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

7 of the 16 studies in Pancreatitis by Changhai Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Pancreatitis by Changhai Hospital, or all of them as a file.
02

Study summary

This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT in patients with moderate to severe acute pancreatitis.

Read the detailed description

This study is a single center, randomized controlled trial. After the start of the study, 80 patients with acute moderate to severe acute pancreatitis were randomly selected according to inclusion and exclusion criteria and divided into an intervention group (n=40) and a control group (n=40) to explore the safety and efficacy of FMT in preventing late complications of acute moderate to severe acute pancreatitis.

03

Conditions studied

  • Acute Pancreatitis
  • Severe Acute Pancreatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age: 18-70 years old Diagnosis: Meets the diagnostic criteria for severe acute pancreatitis (SAP)

  • Organ function: There may be organ failure and systemic complications that can be recovered within 48 hours
  • Stage of the disease: Approximately 2 weeks after onset (non acute phase), accompanied by accumulation of pancreatic fluid volume, and significant improvement in CTSI score compared to before (grade II)
  • Nutritional support: Enteral nutrition tube has been left in place Feasibility of transplantation: No absolute for gut microbiota transplantation
  • : Voluntarily sign a written informed consent form
  • Gastrointestinal status:

Abdominal pressure (bladder pressure measurement)\<12mmHg ◦ Existence of spontaneous defecation/exhaust Significant improvement in abdominal distension compared to before

Exclusion criteria

Exclusion Criteria:

Serious complications: combined gastrointestinal bleeding or intestinal fistula

  • Special population: Pregnant or lactating women
  • Informed refusal: Failure to sign form
  • Basic organ dysfunction: Prior to admission, there were chronic organ dysfunction in the heart, lungs, liver, kidneys, or blood system Malignant tumor: Suffering from incurable malignant tumors
  • Immune abnormalities:

diseases

◦ status (solid organ/bone marrow transplantation history, AIDS, long-term use of immunosuppressants/hormones)

  • Enteral nutrition intolerance: unable to meet 50% of calorie requirements due to severe diarrhea, fibrotic intestinal stenosis, severe gastrointestinal edema, high flow intestinal fistula, etc
  • Systemic infection: meets the diagnostic criteria for systemic inflammatory response syndrome (SIRS)
  • Antibiotic dependence: broad-spectrum antibiotic intervention is required for combined extraintestinal organ infections
  • Immunodeficiency: Congenital or acquired immunodeficiency
  • Mental illness: severe mental disorders
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Physiological saline placebo will be injected through a nasojejunal nutrition tube once a day for five days.

    Procedure: Placebo

  • Experimental
    FMT

    FMT bacterial solution will be injected through a nasojejunal nutrition tube once a day for five days. After intestinal preparation (via nasal feeding of inulin or oligofructose 24 hours before FMT), the subjects underwent 5-6 consecutive FMT treatments (injecting 100ml of standard bacterial solution 1/d into the nasojejunal nutrition tube, with a minimum of 2.5 \* 1012 CFU of viable cells per 50mL of bacterial solution). FMT intervention can be performed when the subject's intestinal function is restored and SIRS indicators are significantly relieved compared to before. During the research period, long-term use of probiotics, antibiotics, and other foods and drugs that interfere with and damage gut microbiota is prohibited. Subjects need to be informed in advance before taking any medication. All subjects need to complete relevant examinations before enrollment. Conduct a comprehensive safety and efficacy evaluation during treatment, after treatment, and one week after treatment.

    Procedure: FMT

Interventions

  • ProcedureFMT

    FMT bacterial solution will be injected through a nasojejunal nutrition tube once a day for five days.

  • ProcedurePlacebo

    Physiological saline placebo will be injected through a nasojejunal nutrition tube once a day for five days.

06

What researchers measure

Primary outcomes

  1. Pancreatic infectious complications

    Infectious pancreatic necrosis, sepsis, and pancreatic fistula. Infectious pancreatic necrosis: (1) Imaging suggests the formation of gas at the site of necrosis aggregation; (2) Gram staining or culture positivity of necrotic specimens obtained through percutaneous fine needle aspiration (FNAC); (3) Clinically suspected infection symptoms. However, due to the high false positive rate, routine FNAC examination is not recommended. Sepsis: (1) Two blood cultures (or bone marrow cultures) are positive for the same pathogen. (2) Systemic inflammatory response syndrome (SIRS) occurs. Pancreatic fistula: (1) History of acute necrotizing pancreatitis attacks; (2) Imaging supports the diagnosis of pancreatic fistula. Measurement: Yes/No (incidence rate)

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Change in CTSI score

    The CT Severity Score (CTSI) of acute pancreatitis can evaluate the severity of acute pancreatitis, predict the probability of complications such as organ failure in the early stages of the disease, and assess the prognosis of patients Method: Measure CTSI scores during baseline and after FMT treatment

    Time frame: through study completion, an average of 1 year

  2. Changes in gut microbiome community

    The average change in bacterial species relative to baseline compared to one week after fecal microbiota transplantation (FMT).

    Time frame: Up to 1 week

  3. Gastrointestinal mucosal barrier index

    Diamine oxidase (DAO): It is a marker enzyme of intestinal mucosal cells. D-Lactic acid: It is a metabolic product of intestinal bacteria. Under normal circumstances, the content in plasma is extremely low. When the intestinal mucosa is damaged, DAO and D-lactate will be released into the blood in large quantities, leading to a significant increase in blood concentration, which is an important indicator for evaluating the structural integrity of the intestinal mucosa. During the treatment process, changes in DAO and D-lactate levels can reflect the progress of intestinal mucosal repair. DAO decline rate Formula: (Baseline Value -7-Day Value)/Baseline Value x 100% Unit:% D-lactic acid decline rate Formula: (Baseline Value -7-Day Value)/Baseline Value x 100% Unit:%

    Time frame: Up to 1 weeks

  4. Markers of inflammatory conditions

    C-reactive protein (CRP) is a measure of inflammatory status and is considered a biomarker of inflammation in patients with pancreatitis.

    Time frame: Up to 3 months

  5. Inflammatory markers

    Procalcitonin (PCT) is a measure of inflammatory status and is considered a biomarker of inflammation in patients with pancreatitis

    Time frame: Up to 3 months

  6. Inflammatory markers

    Interleukin-6 (IL-6) is a measure of inflammatory status and is considered a biomarker of inflammation in patients with pancreatitis

    Time frame: Up to 3 months

  7. Inflammatory markers

    lactic acid is a measure of inflammatory status and is considered a biomarker of inflammation in patients with pancreatitis

    Time frame: Up to 3 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 26 months is below that.

Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2024
First posted
Sep 4, 2025
StartActual
Oct 12, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07153809
Lead sponsor
Changhai Hospital
Responsible party
Xiangyu Kong (Principle Investigator, Changhai Hospital) — Principal investigator
First posted
Sep 4, 2025
Start date
Oct 12, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 4, 2025

Study contacts

Kong Xiang yu, associate professor
Contact
xiangyukong185@hotmail.com
13564644397

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion